# Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL

Source: https://onco.cc/trials/nct04624633/  
OnCo record `nct04624633` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Acalabrutinib and Umbralisib in Chronic lymphocytic leukaemia, run by Jennifer R. Brown, MD, PhD, active and no longer recruiting.

## Summary

Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL is a phase 2 interventional study registered as NCT04624633 by Jennifer R. Brown, MD, PhD, with 29 participants planned, started 2020-12-15 and due to reach its primary completion in 2023-12-21. Interventions recorded: Acalabrutinib, Umbralisib, Ublituximab. Conditions recorded: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia.

Linked to the drug Umbralisib because the registry names it among its interventions and Chronic lymphocytic leukaemia among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04624633
- Phase: 2
- Setting: A Phase 2 Study of Acalabrutinib, Umbralisib, and Ublituximab (AU2) in Relapsed and Previously Untreated CLL Patients
- Sponsor: Jennifer R. Brown, MD, PhD
- Enrolled: 29

## Sources

- ClinicalTrials.gov NCT04624633: https://clinicaltrials.gov/study/NCT04624633

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/)
- drugs: [Acalabrutinib](https://onco.cc/drugs/acalabrutinib/), [Umbralisib](https://onco.cc/drugs/umbralisib/)

---
JSON: https://onco.cc/api/v1/entities/nct04624633.json